Routine board appointment with no immediate financial or operational catalyst. Monitor upcoming clinical milestones for ARD-101 in Prader-Willi Syndrome, which Dr. Zhang's regulatory expertise may support.
Price Chart
Executive Summary
Aardvark Therapeutics appointed David (Zhongwei) Zhang, Ph.D., MBA, as a Class II independent director, effective October 7, 2026. Dr. Zhang brings over 25 years of clinical development and regulatory experience from Abivax, Alumis, MyoKardia, and Genentech/Roche, including pivotal Phase 3 trial design and NDA submissions. The appointment is a routine board addition with standard compensation ($40,000/year cash + $500,000 option grant) and carries no material financial impact.
Key Facts
- David Zhang appointed as Class II independent director effective October 7, 2026
- Receives $40,000/year cash compensation and a $500,000 option grant vesting over 36 months
- Option accelerates upon a Change in Control
- No family relationships or related-party transactions with existing directors/officers
- Press release issued October 8, 2026 announcing the appointment
Financial Impact
Standard non-employee director compensation: $40,000 annual cash retainer and a $500,000 option grant. No material financial impact.
Risk Factors
- No material risks identified from this filing
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-417935 |
| Document: ck0001774857-ex99_1.htm | 0001193125-26-417935 |
| Document: 0001193125-26-417935-index-headers.html | 0001193125-26-417935 |
| Document: 0001193125-26-417935-index.html | 0001193125-26-417935 |
| Document: 0001193125-26-417935.txt | 0001193125-26-417935 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 22, 2026 4d ago | 8-K | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 22, 2026 4d ago | Press Release | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 8, 2026 18d ago | 3 | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.08 (−77.31%) |
Oct 8, 2026 18d ago | 8-K | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.08 (−77.31%) |
Aug 12, 2026 10w ago | Institutional Cluster | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Aug 11, 2026 10w ago | 8-K | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Aug 11, 2026 10w ago | Press Release | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.64 $3.90 | ▲ +7.14% | ▲ +6.60% | $1.08 (−70.33%) |
May 14, 2026 23w ago | Press Release | $4.57 $4.36 | ▲ +4.60% | ▲ +4.53% | $1.08 (+76.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers